WallFlex® and Evolution® Duodenal Stents Have Similar Efficacy but Different Safety for Malignant Gastric Outlet Obstruction
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
BACKGROUND: The WallFlex® and Evolution® stents are the most widely used duodenal stents, but no study has compared them.
AIMS: We aimed to compare the efficacy and safety of WallFlex® and Evolution® stents for malignant gastric outlet obstruction.
METHODS: We included all consecutive patients who were treated for malignant gastric outlet obstruction with WallFlex® or Evolution® self-expandable metal uncovered duodenal stents between 2013 and 2020. Multivariable Cox models were performed to assess duodenal stent failure, as defined by gastric outlet obstruction necessitating another duodenal stent.
RESULTS: We included 129 patients: 74 received a WallFlex® stent and 55 received an Evolution® stent. The non-failure rate was of 68% (95%CI 55-84) and 65% (95%CI 50-84) at 6 months and of 48% (95%CI 32-73) and 45% (95%CI 27-74) at 1 year, with the WallFlex® and Evolution® stents, respectively. The median time to duodenal stent failure was 10.5 months in the WallFlex® group and 9.3 months in the Evolution® group. The type of duodenal stent was not associated with duodenal stent failure (p logrank = 0.43, adjusted hazard ratio 1.55; 95%CI 0.77-3.14). The overall survival was similar between the two groups (p logrank = 0.92). Three patients had complications due to Evolution® stents; it consisted in dismantled stents that led to hemorrhage in one patient.
CONCLUSIONS: WallFlex® and Evolution® duodenal stents had similar efficacy for malignant gastric outlet obstruction. There were more adverse events with Evolution® stents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Digestive diseases and sciences - 68(2023), 9 vom: 21. Sept., Seite 3688-3693 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meyer, Antoine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Duodenal stent |
|---|
| Anmerkungen: |
Date Completed 24.08.2023 Date Revised 26.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10620-023-08036-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359781179 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359781179 | ||
| 003 | DE-627 | ||
| 005 | 20231226081617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10620-023-08036-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359781179 | ||
| 035 | |a (NLM)37477765 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meyer, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a WallFlex® and Evolution® Duodenal Stents Have Similar Efficacy but Different Safety for Malignant Gastric Outlet Obstruction |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2023 | ||
| 500 | |a Date Revised 26.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a BACKGROUND: The WallFlex® and Evolution® stents are the most widely used duodenal stents, but no study has compared them | ||
| 520 | |a AIMS: We aimed to compare the efficacy and safety of WallFlex® and Evolution® stents for malignant gastric outlet obstruction | ||
| 520 | |a METHODS: We included all consecutive patients who were treated for malignant gastric outlet obstruction with WallFlex® or Evolution® self-expandable metal uncovered duodenal stents between 2013 and 2020. Multivariable Cox models were performed to assess duodenal stent failure, as defined by gastric outlet obstruction necessitating another duodenal stent | ||
| 520 | |a RESULTS: We included 129 patients: 74 received a WallFlex® stent and 55 received an Evolution® stent. The non-failure rate was of 68% (95%CI 55-84) and 65% (95%CI 50-84) at 6 months and of 48% (95%CI 32-73) and 45% (95%CI 27-74) at 1 year, with the WallFlex® and Evolution® stents, respectively. The median time to duodenal stent failure was 10.5 months in the WallFlex® group and 9.3 months in the Evolution® group. The type of duodenal stent was not associated with duodenal stent failure (p logrank = 0.43, adjusted hazard ratio 1.55; 95%CI 0.77-3.14). The overall survival was similar between the two groups (p logrank = 0.92). Three patients had complications due to Evolution® stents; it consisted in dismantled stents that led to hemorrhage in one patient | ||
| 520 | |a CONCLUSIONS: WallFlex® and Evolution® duodenal stents had similar efficacy for malignant gastric outlet obstruction. There were more adverse events with Evolution® stents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Duodenal stent | |
| 650 | 4 | |a Evolution | |
| 650 | 4 | |a Gastric outlet obstruction | |
| 650 | 4 | |a Malignancy | |
| 650 | 4 | |a WallFlex | |
| 700 | 1 | |a Martin, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Bellanger, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Carbonnel, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Boytchev, Isabelle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d 1989 |g 68(2023), 9 vom: 21. Sept., Seite 3688-3693 |w (DE-627)NLM000356492 |x 1573-2568 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2023 |g number:9 |g day:21 |g month:09 |g pages:3688-3693 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10620-023-08036-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2023 |e 9 |b 21 |c 09 |h 3688-3693 | ||